S193: BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

Ítems similars

• Targeting GPRC5D for multiple myeloma therapy
  per: Dian Zhou, et al.
  Publicat: (2024-09-01)
• S190: FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  per: Maria-Victoria Mateos, et al.
  Publicat: (2023-08-01)
• The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
  per: Pengfei Yan, et al.
  Publicat: (2024-06-01)
• S191: PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), A GPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)
  per: Cyrille Touzeau, et al.
  Publicat: (2023-08-01)
• GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
  per: Paula Rodriguez-Otero, et al.
  Publicat: (2024-02-01)